COVID-19 update: reinvention for social distancing
Adapting operations and new digital health developments
We are running COVID-19 webinars every Thursday at 11am to bring you key information on the COVID-19 situation for BIA member companies and the life sciences sector. Each week we will also invite guest speakers to join us for discussion around a particular topic of interest to our sector.
This week we will look at operational strategies to recover, reposition and relaunch as the end of lockdown draws nearer. We will also be discussing developments in digital health, and how these can support social distancing in the "new normal"
We will be joined by guest speakers including: Sharon Lamb, Partner, McDermott Will & Emery; and Nick Stephens, Executive Chairman, The RSA Group.
Sharon Lamb focuses her practice on health care transactions, investments and projects, as well as comprehensive health care regulatory advice. She has advised private and public health care clients for more than 17 years.
Sharon advises on global transactional mandates, including mergers and acquisitions, complex digital health and data privacy issues, accountable care systems, health care payment systems, hospital developments and contractual and joint venture arrangements. Sharon also provides strategic and commercial support to UK and international clients on UK health transactions and investments, contracting with the NHS and on health regulatory matters including digital health, medtech and life sciences. Sharon is widely recognized for her expertise on NHS regulatory and contracting matters.
Sharon is also well-versed in health care governance and regulatory matters, NHS projects, procurements, joint ventures and shared working arrangements, mergers, acquisitions, franchise arrangements and competition clearances. She has acted as a lead on a full range of public private partnerships, including PFI and LIFT.
Sharon has a wealth of experience with National Health Service law and policy, having completed a 4-year part time secondment with the NHS and national health bodies in London. Sharon is also an associate fellow of the Nuffield Trust.
Nick Stephens is Executive Chair of The RSA Group, a global leader in Life Sciences Executive Search and Executive Interims. Serving biotech, pharma, medical devices, diagnostic, and academic medical research markets. The RSA Group specialises in C-suite, senior executive and board level searches. His company has developed unique “Data Driven Due Diligence” methodologies that minimise risk and maximise upside in building and developing leadership teams and Boards.
For almost four decades he and his company have helped to build hundreds of companies which have brought new therapies to patients everywhere. His daily conversations with industry leaders across the world have brought him unique insights into what works where and, perhaps more importantly what will add risk. He believes that with the right people in place patients will have quicker access to better medicines.
Nick is a law graduate with broad commercial experience in various roles spanning metals trading, medical devices, pharmaceuticals and the British National Health Service.
He has been a Director of The RSA Group since 1986, joined the business full-time in 1995 and took it over in 2000.
Steve Bates FMed Sci, OBE
Steve Bates has been leading the UK Bioindustry Association as CEO since 2012. He currently chairs the International Council of Biotech Associations and has been a board member of Europabio since 2015. He sits on the UK’s Life Sciences Council. Steve is the visible face of the vibrant UK life sciences industry to government and media. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham.
Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMES. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish.
Before the BIA, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.
Michael joined the BIA in September to lead our policy and public affairs work on Brexit. He has extensive experience spanning a wide range of senior government and communications roles, most recently as a member of the executive team at Innovate UK, the UK’s innovation agency.
Our aim is to help businesses during this difficult time and also highlight important work across our sector that is helping to tackle the outbreak.
To view key information on the COVID-19 situation for BIA member companies and the life sciences sector please visit our dedicated microsite: www.biacovid19.org